Besides, its application along with nivolumab has been approved in patients with intermediate- or poor-risk renal cell carcinoma (RCC) regardless of PD-L1 status [45], as well as in patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib [46]. Here, CD274 is linked to hepatocellular carcinoma.